Diamonds and Dogs


Celldex Therapeutics Inc. (CLDX)

Celldex Therapeutics is exciting its investors today, up 17.40% to $24.90. The biopharmaceutical company saw its shares rally after positive news from the FDA. The FDA granted rindopepimut (Rintega(R)) Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma (GBM). This application was based on data from the Phase 2 ReACT study in recurrent GBM, the Phase 2 ACT III study in newly diagnosed GBM and additional supportive Phase 2 studies. Shares of Celldex climbed nearly $4.00 today but are still off of their 52-week high of $33.33.

CyberArk Software Ltd. (CYBR)

CyberArk is getting hit hard today, down 14.13% to $60.34. The IT/cyber security company saw its shares crash after a ratings cut. Analysts at JPMorgan Chase downgraded the security company to "underweight" from "neutral", but maintained its $42 price target on shares. JPMorgan Chase analysts stated that CyberARK's valuation is in-line with Palo Alto Networks, even though CyberArk is about five times smaller in its addressable market size. Shares of CyberArk fell over $9.40 today but are not even close to their 52-week low of $22.12.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.